Business
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the “Option”). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the
About this update from Avalo Therapeutics, Inc.
[{"type":"image","alt":"Avalo Therapeutics","displaySize":"","headline":null,"caption":"Avalo Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":161,"url":"https://media.zenfs.com/en/globenewswire.com/64359ff9edc0e46c29be0915b2a0157e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UA6MqpDHqWuHcxhDCT69uA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNQ--/https://media.zenfs.com/en/globenewswire.com/64359ff9edc0e46c29be0915b2a0157e","width":300,"height":161},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/UA6MqpDHqWuHcxhDCT69uA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNQ--/https://media.zenfs.com/en/globenewswire.com/64359ff9edc0e46c29be0915b2a0157e","width":300,"height":161}},"lazy":false},{"type":"text","content":"WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the “Option”). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).","length":601,"tagName":"p"},{"type":"text","content":"The Option was granted on May 21, 2026 and has an exercise price of $16.60 per share, which is equal to the closing price of Avalo’s common stock on the grant date. The Option will vest as to 25% of the underlying shares of common stock on the one-year anniversary of the employee’s start date of employment, and the balance of the underlying shares of common stock vesting monthly thereafter over 36 months, subject to the employee’s continued service relationship with Avalo through the applicable vesting dates. The Option is subject to the terms and conditions of Avalo’s 2025 Inducement Award Plan and award agreements thereunder.","length":645,"tagName":"p"},{"type":"text","content":"About Avalo Therapeutics","length":24,"tagName":"p"},{"type":"text","content":"Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is ...